-
Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript
21 Oct 2025 21:35 GMT
… . We'll now start Daiichi Sankyo's ESMO 2025 highlights …
-
AstraZeneca, Daiichi Sankyo announce Enhertu demonstrated improvement in IDFS
19 Oct 2025 23:56 GMT
AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announced positive results from …
-
Sacituzumab govitecan improves outcomes for breast cancer subset
23 Oct 2025 20:23 GMT
… , with AbbVie, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly & Co., Gilead … , with AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, Merck & Co …
-
Executive Advisory Veteran Andrew Zezas Launches CFO IQ Podcast for Finance Leaders
23 Oct 2025 13:00 GMT
… , the Kansas City Chiefs, and Daiichi Sankyo.
“When CFOs discover how peers …
-
The Lancet: Study confirms cardiovascular benefits of semaglutide beyond weight loss
23 Oct 2025 00:38 GMT
… Bayer, BioAtla, Bristol Myers Squibb, Daiichi Sankyo,
Denovo, Fore Therapeutics, and Immunome …
Tanabe; and consulting honoraria from Daiichi Sankyo, MAC, Power-
Biotech, Sanofi … IK declares research grants from Daiichi
Sankyo, Kowa Pharmaceutical, and Tanabe …
-
New Drugs Show Promise In Tough-To-Treat Cancers
22 Oct 2025 16:22 GMT
… , raludotatug deruxtecan, co-developed with Daiichi Sankyo. A phase II/III …
-
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
22 Oct 2025 15:19 GMT
… game is AstraZeneca with its Daiichi Sankyo–partnered ADC Datroway. At ESMO …
-
AstraZeneca Bolsters Oncology with £1.2 Billion Fusion Buyout Amid UK Growth
22 Oct 2025 12:48 GMT
… , which it acquired through its Daiichi Sankyo partnership in 2019.
The agreement …
-
REJOICE─Ovarian01 phase 2/3 trial of raludotatug deruxtecan demonstrated clinically meaningful response rates in patients with recurrent platinum─resistant ovarian, primary peritoneal or fallopian tube cancer
22 Oct 2025 07:46 GMT
… in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely … , is being developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform consists of …
-
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib
22 Oct 2025 07:57 GMT
… reports personal fees from AstraZeneca, Daiichi Sankyo, Pfizer, Lilly, Genentech, Regeneron, Johnson …